Background: This evidence review was conducted to inform the accompanying clinical practice guideline on the management of cyclic vomiting syndrome (CVS) in adults.
| INTRODUC TI ON
Cyclic vomiting syndrome (CVS) is a chronic, debilitating illness that is characterized by recurrent episodes of intense nausea and vomiting. Although the true prevalence of CVS in adults in the general population remains uncertain, it is not a rare disorder. A recent population-based study noted that the US prevalence was 2% among adults, mirroring prevalence estimates in children. 1 Another estimated that ~10% of outpatients presenting to a tertiary gastroenterology clinic met the Rome III criteria for the illness; 2 however, even in this clinical setting, CVS was considered as a potential diagnosis in only a small minority of these patients. For all PICOs, the a priori intent was to rely upon high-quality systematic reviews for evidence synthesis, particularly those that synthesized data from randomized control trials (RCTs). If systematic reviews of RCTs were not available, we would then look to individual RCTs to generate summary estimates if possible. In the absence of systematic reviews of RCTs or individual RCTs, systematic reviews of observational studies and observational studies were then considered to inform the evidence. Case series of fewer than 10 individuals were excluded, as were narrative reviews. 
| Study selection criteria
The reviewers utilized the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) guidelines to develop the review. A PRISMA flow diagram is included in Figure 1 . The titles/ abstracts from the database searches were uploaded to Covidence (http://covidence.org), a Web-based application that facilitates screening and reviewing studies for systematic reviews. All titles and abstracts were screened by two researchers (R.S. and S.S.) with disagreements regarding inclusion and exclusion resolved by discussion. Inclusion criteria included any articles that might be relevant to the included PICO questions. Exclusion criteria were principally around study design as mentioned above. A total of 1469 non-duplicate articles were found, and 572 full-text articles were then reviewed. One author (R.S.) extracted data from full-text articles into a standardized data collection form with accuracy of data extraction confirmed by several members of the systematic review committee.
Study characteristics and data extraction are reported in Table 2a ,b.
| Statistical analysis
Given the size and heterogeneity of included studies, the majority of results were suitable to narrative summary. Quantitative outcomes were calculated using Open Meta (http://www.cebm.brown.edu/openmeta/).
| Quality or certainty of evidence
The GRADE approach was used to rate the certainty in the evidence.
In this approach, direct evidence from RCTs starts at high quality and
can be rated down to levels of moderate, low, and very low quality, 
| Evidence-to-decision framework
Information from this review was used in combination with factors such as patients' values and preferences, cost-effectiveness data (if available), and resource utilization to inform the development of the clinical guideline.
| RE SULTS

| Overview
Study details are presented in Table 2a 
| Prophylactic therapy
| Should tricyclic antidepressants (TCAs) be used as prophylactic therapy in adults with CVS?
Key message
There is very low certainty in the evidence that TCAs should be used as prophylactic therapy in CVS. See Table 3 for full evidence profile.
Potential benefits/harms
Fourteen studies met inclusion criteria and were used to inform this question: These included 2 randomized trials and 12 observational studies. 4 7 However, adverse events leading to treatment discontinuation were not systematically reported across the studies.
Certainty of evidence
The overall certainty of the evidence was judged to be very low. Risk of bias was a concern (lack of control group and possible selection bias in the observational studies, and lack of obvious blinding and an intention to treat analysis in the randomized trials). There was also concern regarding inconsistency, indirectness (many of the studies included only pediatric patients), and imprecision (for a few of the outcomes).
| Should topiramate be used as prophylactic therapy in adults with CVS?
Key message
There is very low certainty in the evidence that topiramate should be used as prophylactic therapy in CVS. See Table 4 for full evidence profile
Potential benefits/harms
One study met inclusion criteria that investigated the role of topiramate in CVS. 15 were significantly higher in the topiramate group 15/16 (94%) compared to the propranolol group 18/22 (81%). In the topiramate arm, 81% became episode free and 13% showed at least ≥ 50% reduction in number of episodes. Per the study, the four patients who were non-responsive to propranolol were treated with topiramate, and all of them had a "satisfactory response," though this was not clearly defined by the authors. The one patient who was non-responsive to topiramate was also non-responsive to other medications, including propranolol, amitriptyline, and cyproheptadine. One additional study reported on topiramate use in adults (Kumar et al.) ; in this study, 18/92 adults were treated with topiramate, but not enough detail was provided to discern the efficacy of topiramate alone, as patients in this cohort also received treatment with amitriptyline and mitochondrial supplements. 12 In the study by Sezer et al., there were no dropouts from adverse events, and no statistically significant difference in adverse events between the propranolol and topiramate groups. 15 Two patients experienced drowsiness and dizziness with topiramate, and mean weight loss after the end of 12 months was 1.1 ± 0.5 kg (2.9%).
TA B L E 3 Should TCAs be used as prophylactic therapy in adults with CVS?
Certainty assessment There were issues around selection bias, no intention to treat analysis, confounding, co-interventions with mitochondrial supplements, and variable follow-up. The outcomes were variably reported across the different studies: from complete response (no attacks), partial response (50% reduction in frequency and duration) to "good response, fair response, poor response," to the use of a visual analog scale to "subjective improvement." c We rated down for inconsistency (high I-squared). d We rated down for indirectness as 6 studies were conducted in the pediatric population. e There were few events, and the sample size was small. The study (Sezer 2016 ) included 16 pediatric patients. Overall responders (≥ 50% reduction) = 94% (partial or complete response). In one additional study (Kumar 2012 ), 17/76 adult patients received topiramate but there was not enough detail provided for the analysis (as patients may also have been treated with amitriptyline and mitochondrial supplements. In this study, overall response was 86% (≥ 50% reduction in frequency of CVS episodes). c There were few events and small numbers of patients.
№ of patients
Certainty in effects
The overall certainty in the effects was very low due to concerns about study quality, imprecision (few events and small sample size), and indirectness (the study population was pediatric patients)
| Should aprepitant be used as prophylactic therapy in adults with CVS?
In patients with CVS, there is very low certainty in the evidence for the use of aprepitant as prophylactic therapy in CVS. See Table 5 for full evidence profile
Potential benefits/harms
One observational study investigated the use of aprepitant both as abortive therapy and as prophylactic therapy in CVS. 16 16, 6%) .
Certainty of evidence
The certainty in the evidence was very low due to concern for risk of bias (lack of a control population, possible selection bias and confounding). There was also concern regarding indirectness, given that the study included a population that failed prior CVS treatments, and was on several concomitant medications. Some adolescents were at an adult weight (>60 kg) in the prophylactic group and were dosed accordingly, making this less of a concern.
3.
| Should zonisamide or levetiracetam be used as prophylactic therapy in adults with CVS?
In patients with CVS, there is very low certainty in the evidence for the use of zonisamide or levetiracetam as prophylactic therapy. See Table 6 for full evidence profile
Potential benefits/harms
One retrospective study met inclusion criteria. 17 
Certainty in the evidence
The certainty in the evidence was very low. We rated down for risk of bias and imprecision (small sample size, raising concern about optimal information size).
TA B L E 5 Should aprepitant be used as prophylactic therapy in adults with CVS?
Certainty assessment Impact Certainty Importance № of studies
Study design
Risk of bias
Inconsistency
Indirectness
Imprecision
Other considerations
Complete response (no episodes) (follow-up: 12 months) 
| Should mitochondrial supplements be used as prophylactic therapy in adults with CVS?
Key message
In patients with CVS, there is very low certainty in the evidence for the use of mitochondrial supplements, such as Co-enzyme Q10, and riboflavin as prophylactic therapy. See Table 7 for full evidence profile.
Potential benefits/harms
The only comparative study to evaluate the efficacy of Coenzyme study included riboflavin but did not report on response for these patients.
The majority of studies that reported on the use of mitochondrial supplements was not amenable to providing estimates on the efficacy of mitochondrial supplements because these were used as co-therapy in conjunction with other agents or because lack of reporting of outcomes specific to mitochondrial therapy. 7, 8, 10, 12, 16, 18 Data on the reported prevalence of mitochondrial supplement therapy as co-interventions are reviewed below. The Lee et al.
(2012) systematic review was not used to inform this outcome because it either included studies that did not meet our inclusion criteria or included studies that as discussed below, used supplements as co-therapy. 19 The studies included adult and pediatric patients. c There were few events and small numbers of patients. population between both of these studies. With respect to adverse effects, in the Boles 2010 study, there were no reported side effects (0/20).
Certainty of evidence
The certainty in the evidence was deemed to be very low due to concerns about study quality, indirectness, and imprecision (retrospective design, lack of a control population, probable selection bias, pediatric population, small sample size, and confounding). No pooled effect estimate or range of effects could be calculated.
| Abortive medications
| Should triptans be used as abortive therapy in adults with CVS?
There is moderate certainty in the evidence for the use of triptans as abortive therapy in CVS, primarily based on indirect data. See Table 8 for full evidence profile.
Potential benefits/harms
We identified four studies that met inclusion criteria and that reported on the use of triptans as abortive therapy in CVS. One systematic review of treatments for CVS was not included below because it only reviewed the Hikita 2011 study. 21 We additionally looked for indirect evidence in the migraine literature to help inform outcomes, such as nausea and vomiting. 22 Kumar 2012 conducted a retrospective review of adult and pediatric patients seen at the Medical College of Wisconsin who met Rome III criteria for CVS. 12 Data were collected on 101 patients through chart review and patient questionnaires. Response data were not available on all patients, though it was noted that triptan medications "aborted" CVS episodes in 64/77 (83%) of patients.
Hikita 2011 studied one adult and eleven pediatric patients in a prospective cohort study that took place at Teikyo University Hospital in Japan. 21 Indirect estimates for the effect of sumatriptan on symptom reduction (nausea and vomiting) were derived from the migraine headache literature. 22 In a systematic review of patients with migraine headaches, but not necessarily CVS, of 8 randomized control trials, 45% to 76% of individuals with migraine headaches experienced a reduction in nausea symptoms within 2 hours with triptans and higher rates of symptom improvement were seen in individuals receiving sumatriptan by either intranasal (50%-60% range) and subcutaneous routes (76%). 22 Among the 3 studies that included data on the use of triptans as abortive therapy in CVS, no adverse events were reported. 12, 23 Furthermore, no data on adverse events leading to treatment discontinuation were provided in the Derry et al. Cochrane systematic review. Adverse effects were generally described as mild or moderate and self-limited. No cardiovascular problems were noted.
Certainty in the evidence
Indirect estimates influenced the certainty of the evidence supporting the utility of triptans as abortive therapy in CVS. With regard to the outcome of relief of nausea at 2 hours, we had moderate certainty in the beneficial effect of triptans, as presented by the summary estimate yielded from a meta-analysis of eight RCTs. We downgraded for indirectness as the population studied was patients with migraine headaches (CVS is in the subgroup of periodic syndromes that include migraine and its equivalents).
With regard to the outcome of treatment response and adverse events (across the three studies in CVS patients), the certainty in the evidence was deemed to be very low. We downgraded due to risk of selection bias, imprecision (concern for fragility in the estimate due to suboptimal information size), and indirectness, because some studies were conducted in pediatric populations and some data come from a CVS-migraine-associated phenotype.
| Should 5-HT3 antagonists be used as abortive therapy in adults with CVS?
No published studies examining the use of ondansetron as abortive therapy for CVS were identified despite its widespread use in CVS.
No GRADE evidence profile was created. The observational studies were at risk for selection bias.
b
The outcome was variably defined across studies: "medication response" or "benefit" which may represent complete/partial response or symptom improvement. Li et al. found that 69% of kids (24/35) had improvement in nausea symptoms (defined as a > 50% reduction in vomiting episodes with subcutaneous sumatriptan). Hikita et al. found 54% of attacks in 11 kids/1 adult were responsive to sumatriptan therapy (defined as complete improvement or at least a 50% reduction in vomiting frequency).
c Some studies were conducted in pediatric populations, and some data come from a CVS-migraine-associated phenotype. d We rated down for imprecision due to the small sample size and few events. e An overview of SRs was used to provide indirect evidence to support the use of triptans for nausea and vomiting. These 8 studies were conducted in individuals with migraine headaches, and nausea relief was a secondary outcome. This was a retrospective cohort study with no control population and concerns about possible selection bias. The study included cohorts who received prophylaxis and abortive treatment. Only the patients who received abortive therapy are presented here. b The patient population included pediatric patients that failed prior CVS treatments and were on several concomitant medications.
| Should aprepitant be used as abortive therapy in adults with CVS?
Key message
In patients with CVS, there is very low certainty in the evidence for the use of aprepitant as abortive therapy. See Table 9 for full evidence profile
Potential benefits/harms
One observational study investigated the use of aprepitant as abortive therapy and as prophylactic therapy in CVS. 16 The study included pediatric patients and was retrospective in design, collecting data from administrative, pharmacy, and clinical databases as well as telephone interviews with patients' parents (see section on aprepitant as prophylactic therapy in CVS for more details). In the abortive group, at a 12-month follow-up time point, 12% (3/25) achieved a complete response and 64% (16/25) achieved a partial response. Overall, 76%
(19/25) achieved either a complete or partial response. Six children had no response (6/25, 24%). It was difficult to discern how often patients received the medication in the abortive group. There were no noted adverse events from aprepitant administration in the abortive group.
Certainty in the evidence
The certainty in the evidence was deemed to be very low, for the same reasons discussed in the prophylactic group. Certainty was reduced by risk of bias (lack of a control population, possible selection bias, and confounding). There was also concern regarding indirectness, given that the study included a population that failed prior CVS treatments, and was on several concomitant medications.
| Should we screen for and treat comorbid conditions, such as anxiety, depression, migraine headache, autonomic dysfunction, sleep disorders, and substance use in adults with CVS?
No published studies were found that explicitly addressed this question. No GRADE evidence profile was created.
| Should meditation, relaxation, and biofeedback be used as complementary therapy in adults with CVS?
No published studies were found that explicitly addressed this question. No GRADE evidence profile was created. 
| Areas of limited/insufficient evidence
| CON CLUS IONS
This evidence review is based on the GRADE framework and was developed to inform the clinical practice guideline for the management of CVS, which should ultimately improve patient outcomes and reduce morbidity associated with this chronic and often, debilitating illness.
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